This article is more than 5 years old. Information may no longer be current.
VIDEO: Expert discusses ‘landmark’ TAVR trials
Click Here to Manage Email Alerts
CHICAGO — In this video exclusive, Howard C. Herrmann, MD, highlights new data on transcatheter aortic valve replacement compared with surgical aortic valve replacement presented at the American College of Cardiology Scientific Session.
Results from the PARTNER 2A cohort demonstrated that TAVR was noninferior to surgical AVR for the combined endpoint of death or disabling stroke in intermediate-risk patients. TAVR was also superior in the transfemoral-access cohort.
“This is a group that had not been previously studied, so it was a very important late-breaking clinical trial,” said Herrmann, the John Winthrop Bryfogle professor of cardiovascular diseases and health system director for interventional cardiology at the Perelman School of Medicine and director of cardiac catheterization laboratories at the Hospital of the University of Pennsylvania.
Herrmann also discusses results of the Sapien 3 cohort of the PARTNER 2 study, which demonstrated that TAVR with the newest-generation balloon-expandable system was superior to surgical AVR at 1 year in intermediate-risk patients.
According to Herrmann, both studies show “great results for patients who were considered intermediate risk for open heart surgery who can now be treated with TAVR.”